Indoco Remedies Share Price

Indoco Remedies Corporate Action

CMP as on 09-Dec-22 15:57

₹ 387.05
-10.90 -2.74%

Open

₹ 398.90

Turnover (lac)

₹ 100

Prev. Close

₹ 397.95

Day's Vol (shares)

₹ 25,812

Day's Range (₹)

₹ 384.00
₹ 398.95

CMP as on09-Dec-22 15:29

₹ 386.80
-10.35 -2.61%

Open

₹ 394.05

Turnover (lac)

₹ 2

Prev. Close

₹ 397.15

Day's Vol (shares)

₹ 967

Day's Range

₹ 383.70
₹ 399.15

Corporate Action

Go
Purpose AGM Date Announcement Date Book Closure Start Date Book Closure End Date
Board Meeting - 20-Oct-2022 - -
INDOCO REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/11/2022 inter alia to consider and approve Intimation of Board Meeting - Unaudited Financial Results for the quarter & half year ended September 30 2022 The Board of Directors at their meeting held today, have approved and taken on record the Standalone & Consolidated Unaudited financial results of the Company for the second quarter/half year ended 30.09.2022. Enclosed please find copies of the following: a) Standalone & Consolidated unaudited results as per Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 b) Limited Review Certificate issued by our Statutory Auditors M/s. Gokhale & Sathe, Chartered Accountants. c) Press Release. The meeting commenced at 10.45 am and concluded at 11.30 am. The Board of Directors at their meeting held today, have approved and taken on record the Standalone & Consolidated Unaudited financial results of the Company for the second quarter/half year ended 30.09.2022. Enclosed please find copies of the following: a) Standalone & Consolidated unaudited results as per Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 b) Limited Review Certificate issued by our Statutory Auditors M/s. Gokhale & Sathe, Chartered Accountants. c) Press Release. In compliance with the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors of the Company at their meeting held today i.e. 10th November, 2022 has inter-alia, considered and approved the following:- Mr. Jayshankar Menon (ICSI Membership No.11067) will retire as the Company Secretary and Compliance Officer of the Company with effect from the closure of business hours of 30th November, 2022. In compliance with the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors of the Company at their meeting held today i.e. 10th November, 2022 has inter-alia, considered and approved the following:- Based on the recommendation of the Nomination and Remuneration Committee and pursuant to Section 203 of the Companies Act, 2013 and Regulation 6(1) of the SEBI LODR Regulations, Mr. Ramanathan Hariharan (ICSI Membership No. A20593) is appointed as the Company Secretary and Compliance Officer of the Company w.e.f. 01st December, 2022 Change in name of Key Managerial Personnel under Regulation 30(5) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (As per BSE Announcement Dated on 10/11/2022)
Board Meeting - 15-Jul-2022 - -
INDOCO REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/08/2022 inter alia to consider and approve Unaudited standalone & consolidated financial results for the quarter ended 30/06/2022 The Board of Directors at their meeting held today, have approved and taken on record the Standalone & Consolidated Unaudited financial results of the Company for the Quarter ended 30th June, 2022. Results for the Quarter ended 30th June 2022 (As Per BSE Announcement Dated on 09.08.2022)
Board Meeting - 22-Apr-2022 - -
INDOCO REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/05/2022 inter alia to consider and approve a) take on record the audited financial results of the Company for the quarter and year ended 31st March 2022. b) Recommendation of Dividend if any for the financial year 2021-2022 We wish to inform that the Board of Directors of the Company at its meeting held today i.e. 17-05-2022 has interalia considered and approved the following: 1. Audited Financial Results (Standalone and Consolidated) for the Quarter and Financial year ended 31st March, 2022 along with Statutory Auditors Report. 2. Subject to the approval of the Members at the ensuing 75th AGM, recommended a Dividend of Rs.2.25 per share (including a Special Dividend of Rs. 0.75) on face value of Rs. 2/- for the Financial year 2021-2022. 3. Subject to the approval of the Members at the ensuing 75th AGM, recommended the re-appointment of M/s Gokhale & Sathe, Chartered Accountants (Firm Registration No. 103264W) as the Statutory Auditors of the Company for the second term of five years commencing from Financial Year 2022-23. 4. Subject to the approval of the Members at the ensuing 75th AGM, approved the Employee Stock Option Scheme. Pursuant to Regulation 33 of Listing Regulations, we enclose herewith the following: 1. Audited Standalone Financial Results of the Company, as per the IND AS for the quarter and year ended 31st March, 2022 along with Auditors Report thereon; 2. Audited Consolidated Financial Results of the Company, as per the IND AS for the year ended 31st March, 2022 and auditors report thereon; 3. Copy of Press Release. Pursuant to Regulation 30(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform that the Board of the Directors of the Company at its Meeting held today i.e. 17th May, 2022, has recommended the re-appointment of M/s. Gokhale & Sathe, Chartered Accountants, (Firm Registration No. 103264W) as the Statutory Auditors of the Company for the second term of Five Years commencing from the conclusion of the ensuing 75th Annual General Meeting (AGM) of the Company till conclusion of the 80th AGM of the Company to be held in the year 2027, subject to the approval of Shareholders at the Annual General Meeting. (As Per BSE Announcement Dated on 17.05.2022)
Board Meeting - 04-Jan-2022 - -
INDOCO REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/02/2022 ,inter alia, to consider and approve Unaudited Financial Results for the quarter ended 31-12-2021 Publication of Board Meeting Notice (As Per BSE Announcement Dated 05.01.2022) Unaudited Results for the Quarter and Nine months ended 31st December 2021 (As Per BSE Announcement dated on 01.02.2022)
Open ZERO Brokerage Demat Account Open Demat Account

Invest wise with Expert advice

By continuing, I accept the Terms & Conditions and agree to receive updates on Whatsapp